Background/Aims: Signal transducer and activator of transcription (STAT) pathway plays an important role in antiviral efficacy of interferon alpha (IFN-α). IFN-α is the main therapeutic against hepatitis C virus (HCV) infection. We explored effects of IFN-α on HCV replication and antiviral gene expression by targeting STAT. Methods: In response to IFN-α, STAT status, HCV replication, and antiviral gene expression were analyzed in human hepatoma Huh7.5.1 cells before and after cell culture-derived HCV infection. Results: IFN-α treatment induced expression and phosphorylation of STAT1 and STAT2 in Huh7.5.1 cells. Pretreatment of Huh7.5.1 cells with a mAb to IFN alpha receptor (IFNAR) 2 decreased IFN-α-dependent phosphorylation of STAT1 and STAT2, whereas pretreatment with an IFNAR1 mAb increased such phosphorylation, suggesting that IFNAR mediates IFN-α-triggered STAT signaling. During HCV infection, STAT1 and STAT2 phosphorylation could be rescued by IFN-α and IFN-α-induced phosphorylation of STAT1 and STAT2 was impaired. Inhibition of STAT pathway by Jak inhibitor I significantly enhanced HCV RNA replication and viral protein expression. Antiviral genes coding for IFN regulatory factor 9 and IFN-stimulated gene 15 were upregulated by IFN-α during HCV infection but such up-regulation was abrogated by Jak inhibitor I. Conclusion: These results establish that activation of STAT pathway is essential for anti-HCV efficacy of IFN-α. Impairment of IFN-α-triggered STAT signaling by HCV may account for evading IFN-α response.
Inhibition of STAT Pathway Impairs AntiHepatitis C Virus Effect of Interferon Alpha

Introduction
Interferon alpha (IFN-α), an important member of type І IFNs, exerts antiviral activity through induction of antiviral gene expression by targeting certain signaling pathways. mouse mAb (Clone 3E5-1) was kindly provided by Dr. Michael Houghton (Chiron Corporation, CA, USA). Rabbit polyclonal antibodies for STAT1, STAT2, phospho-STAT1 (Tyr701), phospho-STAT2 (Tyr690), and β-actin were purchased from Cell Signaling Technology (Beverly, MA, USA). Horseradish peroxidaseconjugated goat anti-rabbit IgG and Alexa Fluor 488-conjugated goat anti-mouse IgG were from Invitrogen (Camarillo, CA, USA). Horseradish peroxidase-conjugated goat anti-mouse IgG was from Bio-Rad (Hercules, CA, USA).
Recombinant human IFN-α2a was obtained from PBL Interferon Source. Jak inhibitor I was from Merck (Calbiochem, Darmstadt, Germany). STAT1 siRNA (Catalog no. 6331) and control siRNA (Catalog no. 6568) were from Cell Signaling Technology. Products used for cell culture were from Invitrogen (Carlsbad, CA, USA).
Flow Cytometry
Human hepatic cell lines Huh7 and Huh7.5.1 were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) at 37°C. Flow cytometry was carried out to detect IFNAR1 and IFNAR2 on Huh7 and Huh7.5.1. Cells were washed with phosphate-buffered saline (PBS), resuspended in 1% bovine serum albumin, and incubated for 1 h with 2.5 μg/ml IFNAR1 mAb or IFNAR2 mAb. Normal mouse serum (Jackson ImmunoResearch, West Grove, PA, USA) was used as a negative control. After two washes with PBS, cells were stained with 5 μg/ml Alexa Fluor 488-conjugated goat antimouse IgG for 30 min at 4°C in the dark, washed three times with PBS, fixed in 1% paraformaldehyde, and analyzed on a flow cytometer (Beckman Coulter FC500, CA, USA) using CellLab Quanta analysis software.
Cell Treatment
To analyze responses of STATs to IFN-α, Huh7 and Huh7.5.1 cells were maintained for 12 h in DMEM and then cultured in DMEM containing 800 U/ml IFN-α for 6, 12, 24, or 36 h. Cells were serum-starved for 12 h before stimulation with 800 U/ml IFN-α dissolved in 0.1% bovine serum albumin for 15, 30, or 60 min at 37°C. For receptor blockage experiments, cells serum-starved were pretreated for 1 h with IFNAR1 mAb or IFNAR2 mAb (0, 1, 10, and 20 μg/ml), washed twice with PBS, and stimulated with 800 U/ml IFN-α for 15 min. For HCVcc (J6/JFH1) infection, Huh7.5.1 that is a permissive cell line for HCVcc replication was cultured for 12 h with 100 U/ml IFN-α in 10% FBS-DMEM before incubation with the virus stock (multiplicity of infection of 0.3) for 2 h of adsorption at 37°C. After washing with PBS to remove unbound virus, cells were cultured in the fresh medium containing 100 U/ml IFN-α for 48 h and 72 h, respectively.
Jak Inhibitor I Treatment
To evaluate effect of Jak inhibitor I on STAT signaling triggered by IFN-α, Huh7.5.1 cells serum-starved were pretreated for 30 min with increasing amounts of Jak inhibitor I dissolved in DMSO, washed twice with PBS, and stimulated with 800 U/ml IFN-α for 15 min at 37°C. To assess influence of Jak inhibitor I on HCVcc replication, cells were pretreated with 10 μM Jak inhibitor I for 1 h, washed twice with PBS, cultured with 100 U/ml IFN-α in 10% FBS-DMEM for 12 h prior to HCVcc infection, followed by incubation with the fresh medium containing 10 μM Jak inhibitor I and 100 U/ml IFN-α for 72 h.
Cell Viability Assay Huh7.5.1 cells were cultured for 72 h in 10% FBS-DMEM containing increasing amounts of Jak inhibitor I. Cell viability was determined by CellTiter 96  AQueous One Solution Cell Proliferation Assay (Promega, Madison, WI, USA).
siRNA Transfection
Transfection of siRNA was carried out using Lipofectamine 2000 following the manufacturer's protocol (Invitrogen, Carlsbad, CA). Huh7.5.1 cells were transfected with STAT1 siRNA or control siRNA at a final concentration of 100 nM. After 72 h of transfection, the cells were infected with HCVcc and cultured with 100 U/ml IFN-α for another 72 h. dodecyl sulfate loading buffer containing dithiothreitol reducing agent on ice. Samples were boiled for 5 min, chilled on ice, centrifuged for 10 min at 12,000 rpm, and supernatants were collected for Western blotting. Protein samples were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, electrotransferred to polyvinylidene difluoride membranes, and blocked with 5% nonfat dry milk. Membranes were incubated overnight at 4°C with primary antibodies including rabbit antibody (1:1000) for STAT1 or STAT2 and mouse mAb to HCV NS3 (1:1000) or E2 (1:500). After washing with 0.1% Tween-20 in Trisbuffered saline, the membranes were incubated for 2 h with horseradish peroxidase-conjugated goat antirabbit IgG (1:1000) or goat anti-mouse IgG (1:2000) . Signals were detected by enhanced chemiluminescent detection reagents (Pierce, Rockford, IL, USA) on a GeneGnome HR image capture (Cambridge, UK). The quantitative analysis of protein bands was carried out using GeneTools software (SynGene, Cambridge, UK). β-actin was determined as a control for protein loading.
RNA Extraction and Real-Time Polymerase Chain Reaction
Total cellular RNA was isolated using Trizol reagent (Invitrogen) according to the manufacturer's instructions. RNA concentration was determined on a Synergy 2 Multi-Mode Microplate Reader (BioTek, Winooski, VT, USA). Reverse transcriptase reaction was performed with 1 μg of total RNA using M-MLV reverse transcriptase (Promega). For measurement of mRNA levels of target genes, real-time polymerase chain reaction (PCR) amplification was performed on cDNA templates using QuantiTect SYBR Green PCR kit (BioTeke, Beijing, China). Primer sequences for HCV, IRF9, and ISG15 were described previously [13] . After denaturation at 95°C for 2 min, 40 cycles of PCR were performed with cycling conditions of 10 s at 95°C, 10 s at 55°C, and 25 s at 72°C. The signals were analyzed in Rotor-Gene 3000 Thermal Cycler (Corbett, Sydney, Australia) using Rotor-Gene 6.1.81 software. For each sample, real-time PCR analysis was performed four times. Results were normalized to endogenous reference glyceraldehyde-3-phosphate dehydrogenase.
Statistical Analysis
Data are expressed as mean ± SD. Statistical analysis was performed using Student's t test. Values of P < 0.05 were considered statistically significant.
Results
IFN-α Activates STAT1 and STAT2
STAT1 and STAT2 are the main effectors of type I IFN transcriptional response. Activation of STATs is driven by phosphorylation at critical tyrosine residues. First, expression and phosphorylation of STATs were analyzed in Huh7.5.1 and Huh7 cells. Total and phosphorylated STAT1 and STAT2 were measured by Western blotting on lysates from cells incubated with 800 U/ml IFN-α or left un-incubated at the indicated time points. Fig. 1A showed that basal levels of STAT1 and STAT2 phosphorylation were very low and that IFN-α incubation led to increased phosphorylation of STAT1 and STAT2. In Huh7.5.1 cells, incubation with IFN-α caused a 3.24-to 5.87-fold increase in STAT1 phosphorylation with maximal phosphorylation at 36 h. We found a 2.79-to 7.04-fold increase in STAT2 phosphorylation with maximal phosphorylation at 6 h. In Huh7 cells incubated with IFN-α, phosphorylated STATs peaked at 36 h with a 9.28-or 10.38-fold increase in STAT1 or STAT2 phosphorylation. Amounts of total STAT1 and STAT2 were increased in the cells after exposure to IFN-α. Compared with those in Huh7.5.1 cells, the total and phosphorylated STAT1 and STAT2 were markedly increased in Huh7 cells upon IFN-α treatment. Next, responses of STATs were evaluated in Huh7.5.1 and Huh7 cells exposed to 800 U/ml IFN-α for the short durations (15, 30 , and 60 min). After IFN-α treatment, STAT1 phosphorylation peaked at 15 min and declined thereafter in the two cell lines (Fig. 1B) . Treatment with IFN-α for 15 min led to a modest phosphorylation of STAT2 and that the maintained phosphorylation was detectable at 60 min in Huh7 but not in Huh7. 
Cellular Physiology and Biochemistry
To examine pharmacological inhibition of STAT pathway, Huh7.5.1 cells were treated with the increasing amounts of Jak inhibitor I (an inhibitor of Jak1 and Tyk2) prior to addition of IFN-α. Fig. 2A showed that Jak inhibitor I dose-dependently inhibited IFN-α-induced phosphorylation of STAT1 and STAT2 without affecting total STAT1 and STAT2, particularly the inhibitor at 1 μM almost abolished such phosphorylation, suggesting that Jak inhibitor I potently inhibits STAT signaling triggered by IFN-α. Cells were treated with 1 or 10 μM Jak inhibitor I alone as controls. No detectable changes in STAT1 and STAT2 phosphorylation were seen between the untreated and the inhibitor-treated cells. Thus, IFN-α specifically activates STAT1 and STAT2 in Huh7.5.1 cells.
IFNAR Mediates STAT Signaling Triggered by IFN-α
IFN-α is known to elicit biological responses via cognate receptors including IFNAR1 and IFNAR2. Here functional relevance of IFNAR for IFN-α-triggered STAT signaling was tested in Huh7.5.1 cells. First, flow cytometry was carried out to detect the extracellular domains of IFN-α receptor subunits IFNAR1 and IFNAR2. Consistent with our previous data showing the pattern of IFNAR expression [14] , only IFNAR2 was detectable on Huh7.5.1 cells (Fig. 3A) . Both IFNAR1 and IFNAR2 were detectable on Huh7 cells. The differences in IFNAR expression may account for the strong induction of expression and phosphorylation of STAT1 and STAT2 by IFN-α in Huh7 cells (Fig. 1A) , implying that IFNAR expression is closely associated with regulation of STATs by IFN-α.
We next detected status of STATs in Huh7.5.1 cells pretreated with the mAbs for IFNAR prior to IFN-α treatment. As shown in Fig. 3B , 800 U/ml IFN-α treatment for 15 min resulted in phosphorylation of STAT1 and STAT2. In accordance with the IFNAR expression on Huh7.5.1 cells, the IFNAR2 mAb inhibited IFN-α-induced STAT1 and STAT2 phosphorylation in a dosedependent manner with a maximal inhibitory effect at 20 μg/ml, while such inhibition was not seen upon the IFNAR1 mAb pretreatment. In the cells treated with the IFNAR1 mAb or IFNAR2 mAb alone as controls, no phosphorylation of STAT1 and STAT2 was detectable, ruling out potential effects of the mAbs on STATs. Engagement of IFNAR1 by the IFNAR1 mAb and IFN-α may provide co-stimulated signals for STAT1 and STAT2, as revealed that the IFNAR1 mAb at the indicated concentrations increased the IFN-α-dependent STAT1 and STAT2 phosphorylation. Conversely, the IFNAR2 mAb may compete for IFNAR2 with IFN-α, resulting in the inhibition of IFN-α-dependent STAT1 and STAT2 phosphorylation. In case of Huh7 cells, the IFNAR2 mAb also inhibited the IFN-α-dependent STAT1 phosphorylation (Fig. 3C) . These data implicate the importance of IFNAR in STAT signaling triggered by IFN-α.
IFN-α Activates STAT Signaling during HCV Infection
The STAT pathway was up-regulated by IFN-α in Huh7.5.1 cells (Fig. 1) . We sought to assess IFN-α-triggered STAT signaling at early and late stages of HCV infection. As shown in Fig. 4A (left panel) , a slight increase in STAT1 phosphorylation was seen at 2, 3, or 4 h of HCVcc infection with undetectable STAT2 phosphorylation as compared with the uninfected control. STAT1 phosphorylation induced by IFN-α was impaired in HCVccinfected Huh7.5.1 cells with abolishment of STAT2 phosphorylation (Fig. 4A, right panel) . There was no significant difference in levels of total STAT1 or STAT2 between the uninfected and the HCVcc-infected cells at the indicated time points. While the levels of total STAT1 or STAT2 were obviously increased in the presence of IFN-α (Fig. 4A) . Fig. 4B showed that phosphorylation levels of STAT1 or STAT2 were obviously elevated upon IFN-α incubation at 
STAT Pathway Is Involved in Anti-HCV Action of IFN-α
By using HCVcc, Marcello et al. [7] reported that IFN-α inhibited HCV RNA replication in Huh7.5 cells without providing changes in HCV protein expression. In Huh7.5.1 cells infected with HCVcc, kinetics of HCV replication and anti-HCV action of IFN-α were monitored at both HCV mRNA and HCV protein levels. Reverse transcription real-time PCR was performed to detect HCV mRNA on cellular RNA. As shown in Fig. 5A , levels of HCV mRNA were significant high at 72 h when compared with those at 48 h (P < 0.001), and that treatment with 100 U/ ml IFN-α decreased HCV mRNA levels to 1.35 % and 2.5 % at 48 h and 72 h, respectively. In the same experiments, cell lysates were prepared for assessment of HCV proteins. In parallel with these findings, Western blot analysis confirmed that HCV nonstructural protein NS3 and envelope protein E2 were expressed at 48 h with higher levels of the protein expression at 72 h, and that the IFN-α treatment led to robust inhibition of the NS3 expression and the elimination of the E2 production (Fig. 5B) . Based on these data, the following experiments were carried out to detect HCV replication at 72 h of HCVcc infection.
As illustrated in Fig. 2A , Jak inhibitor I potently inhibited the STAT signaling triggered by IFN-α. To identify role of STAT pathway in HCV replication and in anti-HCV action of IFN-α, HCV replication was evaluated in the presence of Jak inhibitor I. We found that Jak inhibitor I was nontoxic to Huh7.5.1 cells at concentrations up to 10 µM (Fig. 2B) . Interestingly, HCV mRNA levels were significantly increased in the cells treated with 10 µM Jak inhibitor I when compared with the HCVcc-infected cells (P < 0.05, Fig. 5C ). IFN-α markedly inhibited HCV replication in the absence (P < 0.001) or presence (P < 0.005) of Jak inhibitor I, whereas the levels of HCV mRNA were much higher in the cells treated with the inhibitor than those without the inhibitor treatment (P < 0.001). Moreover, similar results were observed at HCV protein expression levels. Fig. 5D showed that the Jak inhibitor I treatment led to increases in the HCV NS3 and E2 production, indicating that HCV RNA replication and the viral protein expression are increased by Jak inhibitor I. IFN-α treatment only reduced the NS3 and E2 expression in the presence of the inhibitor but abolished such expression in the absence of the inhibitor, which was consistent with the abundance of HCV mRNA in the cells with and without the inhibitor treatment. As the inhibitor was dissolved in DMSO, cells were treated with DMSO as a control to rule out its inhibitory effect. Indeed, DMSO had no an inhibitory effect on the anti-HCV action of IFN-α. Together with the activation of STAT signaling by IFN-α (Fig. 4B) , our results establish a direct link between inhibition of HCV and activation of STAT by IFN-α. Influence of STAT1 knockdown on the anti-HCV effect of IFN-α was evaluated. Western blot analysis confirmed knockdown of STAT1 expression when the specific siRNA was transfected (Fig. 6A) . Effect of IFN-α on the signaling was evaluated following STAT1 knockdown. IFN-α treatment failed to increase expression and phosphorylation of STAT1 in the STAT1 siRNA-transfected cells, while control siRNA transfection did not impair the effect of IFN-α on STAT1 (Fig. 6B ). STAT1 siRNA transfection exhibited an inhibitory effect on HCV RNA replication (P < 0.05, Fig. 6C ). There was no difference in HCV inhibition by IFN-α between the STAT1 siRNA transfection and the untransfection. Consistent with the HCV mRNA levels in the cells transfected with STAT1 siRNA, both HCV NS3 and E2 proteins were reduced and eliminated by the IFN-α treatment (Fig. 6D) . Indeed, control siRNA transfection did not affect the anti-HCV effect of IFN-α.
IFN-α Induces Antiviral Genes via STAT Pathway
We further assessed whether there was a correlation between induction of antiviral genes and activation of STAT signaling by IFN-α. The cellular RNA for HCV mRNA detection (Fig. 5A ) was also used to detect mRNA levels of IRF9 and ISG15. Fig. 7A showed that IFN-α incubation greatly increased IRF9 and ISG15 mRNA levels in Huh7.5.1 cells, and the much higher levels of IRF9 and ISG15 mRNA were detectable in HCVcc-infected cells. In response to IFN-α, a maximal induction of IRF9 (13.5-fold) or ISG15 (25.1-fold) was observed at 48 h and 72 h of HCVcc infection, respectively. We next evaluated responses of IRF9 and ISG15 to IFN-α following the Jak inhibitor I treatment. The cellular RNA for detection of IRF9 and ISG15 mRNA levels was the same as that for HCV detection (Fig. 5C ). Jak inhibitor I treatment strongly reduced the mRNA levels of IRF9 and ISG15 induced by IFN-α (Fig. 7B) , indicating that IFN-α induces IRF9 and ISG15 expression by targeting STAT pathway. We found a 5.1-to 7.3-fold reduction in the IRF9 or ISG15 mRNA levels due to the inhibitor treatment. As a control, HCVcc-infected cells were treated with Jak inhibitor I alone. There was no inhibitory effect of the inhibitor on IRF9 and ISG15 expression. The suppression of antiviral gene induction was consistent with the impairment of IFN-α-dependent anti-HCV action by Jak inhibitor I (Fig. 5C and D) . Our findings demonstrate that the activation of STAT signaling is responsible for the induction of antiviral genes by IFN-α.
Discussion
The exact mechanisms by which IFN-α targets STAT pathway to induce antiviral state and HCV attenuates IFN-α response to resist host antiviral defense remain to be elucidated. We demonstrate that both the HCV inhibition and the antiviral gene induction by IFN-α are mediated through the activation of STAT signaling. While HCV impairs the STAT signaling triggered by IFN-α.
Activation of STAT1 and STAT2 is essential for antiviral action of IFN-α [15, 16] . STAT1 and STAT2 were systematically analyzed in human hepatoma cells upon IFN-α treatment. We observed that STAT1 and STAT2 were rapidly phosphorylated following the IFN-α-treatment for the short durations. The prolonged treatment with IFN-α led to the increases in phosphorylation and expression of STAT1 and STAT2. The specific activation of STAT1 and STAT2 by IFN-α was confirmed by the use of Jak inhibitor I. Furthermore, we examined the roles of IFNAR in the mediating IFN-α signal to STAT pathway. The patterns of IFNAR1 and IFNAR2 expression were responsible for the differential activation of STAT1 and STAT2 by IFN-α, as revealed the strong induction of expression and phosphorylation of STATs by IFN-α in Huh7 expressing IFNAR1 and IFNAR2. Supporting the previous study that IFN-α-mediated STAT1 phosphorylation was blocked by the antibody to IFNAR2 [7] , our data showed that the IFNAR2 mAb dose-dependently reduced the phosphorylation of STAT1 and STAT2 by IFN-α in Huh7.5.1 with IFNAR2 expression, while the combination of IFNAR1 mAb and IFN-α increased the phosphorylation of STAT1 and STAT2. These data implicate multiple functions of IFNAR1 and IFNAR2 at an early stage of IFN-α signaling. IFN-α exerts its biological effects through interaction with IFNAR. Work from others has reported that decreased expression of IFNAR in liver from chronic hepatitis C patients exhibits resistance to IFN-α therapy [17, 18] . HCV down-regulates expression of IFNAR1 or/and IFNAR2, thus impairing Jak-STAT signaling [10, 19] .
Due to important contributions of signaling events to virus-host interaction and cell antiviral response [20, 21] , interaction of viruses or viral proteins with components of STAT pathway has been a subject of intensive research. Many viruses are reported to impair STAT signaling by targeting expression or/and phosphorylation of the components. For example, infection with respiratory syncytial virus, varicella-zoster virus, or HCV down-regulates expression of STAT2, STAT1 and Jak2, STAT1 and STAT3, respectively [22] [23] [24] [25] . Hepatitis delta virus impairs phosphorylation of STAT1 and STAT2 [25] . We found that the expression of STAT1 and STAT2 was suppressed at 72 h of HCVcc infection. Such down-regulation of STAT pathway may allow viral survival and replication, thereby facilitating establishment of successful viral infection through subversion of IFN-dependent immunity. Moreover, Marburg virus inhibits IFN-α-induced phosphorylation of STAT1 and STAT2 [26] . Hepatitis E virus prevents IFN-α-induced STAT1 phosphorylation [27] . Our data indicate that HCVcc impairs the IFN-α-induced phosphorylation of STAT1 and STAT2. Similarly, HCV proteins or HCV replicon also inhibits IFN-α-triggered STAT signaling and inhibition occurs in the downstream of STATs phosphorylation as well as in the binding of STATs to the promoters of ISGs [19, 28, 29] . These results provide evidence to support the notion that STAT pathway plays critical roles in innate immune response to virus infection and in IFN-α signaling events.
